NEW YORK (GenomeWeb News) – CombiMatrix said after the close of the market on Friday that it raised $1.45 million in a second tranche of its Series A Preferred Stock.
Registering provides access to this and other free content.
Already have an account?Login Now.
Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.
An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.
At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.
In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.